Shimadzu's triple quads achieve a new global standard in mass spectrometry - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Shimadzu’s triple quads achieve a new global standard in mass spectrometry

Two new triple quadrupole mass spectrometers GCMS-TQ8040 and LCMS-8050 and complete Shimadzu’s UFMS series consisting of seven powerful systems. The UFMS product family provides higher sensitivity, greater excellence in data quality, increased analytical throughput and a wider range of applications.

The LCMS-8050 expand the analytical range of Shimadzu's LC-MS/MS lineup while the GCMS-TQ8040 achieves new levels of speed and sensitivity in GCMS analysis.

GCMS-TQ8040 Simultaneous multicomponent analysis and ultra-high-sensitivity analysis
Improving precision and throughput, Shimadzu’s new GCMS-TQ8040 is the most accurate, cost effective, easy-to-use triple quadrupole GCMS ever. The system combines Ultra-Fast Mass Spectrometry (UFMS) and Smart Multiple Reaction Monitoring (MRM) based on Shimadzu's patented UFsweeperTM technology. Smart MRM streamlines the entire process of adjusting the loop and dwell times for optimum sensitivity, and methods are created with the touch of a button.

Through smart technologies, the triple quadrupole GCMS provides a new level in routine work:

  • Smart Productivity means high efficiency and sample throughput and is based on simultaneous multi-component analysis.
  • Smart Operation facilitates rapid and easy method development.
  • Smart Performance enables Scan/MRM for low detection limits and simultaneous target compound confirmation.

The GCMS-TQ8040 has an eco-friendly design resulting in reduced power consumption and lower running costs.

LCMS-8050 - Trace level quantitation of multiple compounds
Shimadzu’s LCMS-8050 triple quadrupole LC-MS/MS meets the growing demand for trace-level quantitation in clinical research and other markets. It incorporates proprietary ultrafast technologies as well as a newly developed ion source and collision cell technology. As the flagship model of Shimadzu’s UFMS (Ultra-Fast Mass Spectrometry) product line, the LCMS-8050 features high sensitivity, high data quality and the world’s fastest data acquisition rates.

Delivering attogram-level (10-18 grams) sensitivity and possessing unsurpassed ruggedness, the
LCMS-8050 achieves its improved sensitivity through two important technologies:

  • Newly designed Heated ESI source improves desolvation and enhances ionization efficiency with the addition of a heated gas used in combination with the nebulizer gas
  • UFsweeper®III collision cell enhances CID efficiency by optimizing the collision cell pressure.

The world’s fastest data acquisition rates
The newly engineered high voltage power supply enables a maximum scan rate of 30,000 u/sec and a 5 msec polarity switching time, making the LCMS-8050 combined with Nexera UHPLC the ideal platform for laboratory productivity. It is now possible to include 1,000 events with up to 32 channels per event for a maximum of 32,000 MRMs per analysis.

For more information please visit

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here